NantHealth Appoints Dr. Sandeep Reddy as Chief Medical Officer

Wednesday, October 28, 2020

“Appointing Dr. Reddy and his experience to our leadership team will be highly valuable to the evolution of the GPS Cancer initiative,” said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth. “With extensive background in hematology, medical oncology and therapeutics research, Dr. Reddy will play a key role in helping NantHealth achieve victory in the war against cancer.”

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today the appointment of Sandeep (Bobby) Reddy, MD, as Chief Medical Officer. In his new position, Dr. Reddy will be responsible for overseeing education, outreach, clinical development programs, and clinical trials for GPS Cancer™, a comprehensive, molecular profile and NantHealth’s proprietary revolutionary pan-omic cancer analytic platform.

“Appointing Dr. Reddy and his experience to our leadership team will be highly valuable to the evolution of the GPS Cancer initiative,” said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth. “With extensive background in hematology, medical oncology and therapeutics research, Dr. Reddy will play a key role in helping NantHealth achieve victory in the war against cancer.”

Dr. Reddy joined NantHealth in December of 2016 as Senior Executive Director of Medical Affairs and prior to that position, he served as Chief Medical Officer at Caris Life Sciences. Over the course of his career, Dr. Reddy has produced over 100 abstracts at major medical conferences and over 30 peer-reviewed publications since 2014.

“The milestones that NantHealth has achieved in just over a year have established the company as a proven disrupter – national and international insurance coverage of the GPS Cancer profile, multiple partnerships with leading medical institutions and joining experts in the cancer community are immense efforts to take on and in such a condensed timeframe,” said Dr. Reddy. “I’m thrilled to be a part of an initiative that has potential to change the way we approach and treat cancer. Dr. Soon-Shiong is a true visionary and I’m looking forward to working with such an inspirational group of leaders to build further awareness of the benefits that GPS Cancer has to offer the oncology market.”

Dr. Reddy’s additional experience includes servicing as Chief of Staff at Los Alamitos Medical Center and actively practicing clinical hematology and oncology. Simultaneously, he held an adjunct faculty position at the Geffen/UCLA School of Medicine as a clinical instructor at Harbor-UCLA Medical Center, where he was awarded the distinguished teaching award for clinical faculty in 2006. He is a member of the Los Angeles Biomedical Institute, American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC) and current SWOG investigator. His medical training includes fellowship training in hematology and medical oncology and therapeutics research at the City of Hope in Duarte, CA and Internal Medicine residency at Harbor-UCLA Medical Center. Dr. Reddy received his MD from the Geffen/UCLA School of Medicine after receiving his BS in biomedical sciences at the University of California, Riverside.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.